Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRMANASDAQ:EVFMNASDAQ:TCRTNASDAQ:TTNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRMADermata Therapeutics$0.70-1.4%$0.80$0.66▼$5.00$4.45M0.571.18 million shs183,151 shsEVFMEvofem Biosciences$0.01+2.1%$0.01$0.01▼$0.02$1.14M-1463,506 shs65,143 shsTCRTAlaunos Therapeutics$2.71+0.7%$2.69$1.31▼$11.00$4.41M-1.08136,655 shs17,739 shsTTNPTitan Pharmaceuticals$4.91+2.1%$4.14$3.03▼$14.80$4.49M1.25139,314 shs135,848 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRMADermata Therapeutics-1.41%-5.29%-23.12%-42.31%-81.24%EVFMEvofem Biosciences+2.13%+9.09%+11.63%+7.87%-25.81%TCRTAlaunos Therapeutics+0.74%+5.04%-6.55%+67.28%-74.67%TTNPTitan Pharmaceuticals+2.08%+7.56%+28.20%+43.99%-26.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRMADermata Therapeutics2.4048 of 5 stars3.55.00.00.01.50.00.6EVFMEvofem Biosciences1.089 of 5 stars0.05.00.04.80.60.00.0TCRTAlaunos Therapeutics0.3385 of 5 stars0.03.00.00.00.60.80.6TTNPTitan Pharmaceuticals0.6447 of 5 stars0.04.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRMADermata Therapeutics 3.00Buy$3.00329.80% UpsideEVFMEvofem Biosciences 0.00N/AN/AN/ATCRTAlaunos Therapeutics 0.00N/AN/AN/ATTNPTitan Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EVFM, DRMA, TTNP, and TCRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRMADermata TherapeuticsN/AN/AN/AN/A$24.24 per shareN/AEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00TCRTAlaunos Therapeutics$11K404.04N/AN/A$3.93 per share0.69TTNPTitan Pharmaceuticals$180K24.93N/AN/A$8.82 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRMADermata Therapeutics-$7.80M-$16.41N/A∞N/AN/A-247.39%-179.72%N/AEVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/ATCRTAlaunos Therapeutics-$35.14MN/A0.00∞N/AN/A-267.77%-209.18%8/14/2025 (Estimated)TTNPTitan Pharmaceuticals-$5.57M-$4.59N/A∞N/AN/A-118.01%-103.79%8/13/2025 (Estimated)Latest EVFM, DRMA, TTNP, and TCRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TCRTAlaunos Therapeutics-$4.50-$0.67+$3.83-$0.67N/A$0.00 million5/14/2025Q1 2025DRMADermata Therapeutics-$0.45-$0.45N/A-$0.45N/AN/A5/14/2025Q1 2025TTNPTitan PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A3/20/2025Q4 2024TTNPTitan PharmaceuticalsN/A-$0.85N/A-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRMADermata TherapeuticsN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRMADermata TherapeuticsN/A3.443.44EVFMEvofem BiosciencesN/A0.110.09TCRTAlaunos TherapeuticsN/A4.304.30TTNPTitan PharmaceuticalsN/A9.719.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRMADermata Therapeutics8.67%EVFMEvofem Biosciences0.22%TCRTAlaunos Therapeutics27.72%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipDRMADermata Therapeutics9.40%EVFMEvofem Biosciences0.21%TCRTAlaunos Therapeutics16.14%TTNPTitan Pharmaceuticals0.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRMADermata Therapeutics86.38 million1.85 millionNot OptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableTCRTAlaunos Therapeutics401.64 million1.52 millionNo DataTTNPTitan Pharmaceuticals10914,000686,000OptionableEVFM, DRMA, TTNP, and TCRT HeadlinesRecent News About These Companiestitan pharmaceuticals issues common stock following preferred stock conversionsJune 4 at 10:27 AM | investing.comTitan announces filing of registration statement for proposed combinationJune 4 at 10:27 AM | finance.yahoo.comTitan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.June 3 at 9:12 AM | quiverquant.comTitan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.June 3 at 8:45 AM | globenewswire.comTitan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred StockApril 11, 2025 | globenewswire.comTitan Pharmaceuticals: Q4 Earnings SnapshotMarch 20, 2025 | sfgate.comTitan Pharmaceuticals receives Nasdaq notice of non-complianceNovember 27, 2024 | markets.businessinsider.comTitan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee RequirementsNovember 27, 2024 | quiverquant.comTitan Pharmaceuticals, Inc. Announces Receipt of Notice from NasdaqNovember 27, 2024 | globenewswire.comSanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatOctober 25, 2024 | msn.comTitan Pharmaceuticals, Inc. (TTNP)October 17, 2024 | finance.yahoo.com(TTNP) Technical Pivots with Risk ControlsSeptember 25, 2024 | news.stocktradersdaily.comWhen (TTNP) Moves Investors should ListenSeptember 15, 2024 | news.stocktradersdaily.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, FRZA, TTNP on Behalf of ShareholdersSeptember 9, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, CFB, TTNP, DFS on Behalf of ShareholdersSeptember 5, 2024 | stockhouse.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNPSeptember 5, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNPSeptember 4, 2024 | prnewswire.comTitan Pharmaceuticals Share Price (TTNP.US)August 24, 2024 | lse.co.ukShareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public ShareholdersAugust 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Titan Pharmaceuticals, Inc. MergerAugust 22, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVFM, DRMA, TTNP, and TCRT Company DescriptionsDermata Therapeutics NASDAQ:DRMA$0.70 -0.01 (-1.41%) Closing price 06/5/2025 03:52 PM EasternExtended Trading$0.67 -0.02 (-3.44%) As of 06/5/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Evofem Biosciences NASDAQ:EVFM$0.0096 +0.00 (+2.13%) As of 06/5/2025 03:52 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Alaunos Therapeutics NASDAQ:TCRT$2.71 +0.02 (+0.74%) Closing price 06/5/2025 03:59 PM EasternExtended Trading$2.82 +0.11 (+4.21%) As of 06/5/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.Titan Pharmaceuticals NASDAQ:TTNP$4.91 +0.10 (+2.08%) Closing price 06/5/2025 03:59 PM EasternExtended Trading$4.87 -0.04 (-0.81%) As of 06/5/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
